Alpha 2.0
Login Register
» Authors » Alexandros Ardavanis

Alexandros Ardavanis

Explore the profile of Alexandros Ardavanis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 82
Citations 1128
Followers 0
Related Specialties
Oncology
Pharmacology
General Medicine
Top 10 Co-Authors
Andreas Scorilas
Stefania Kokkali
Panteleimon Kountourakis
Constantin N Baxevanis
Sonia A Perez
Ioannis Boukovinas
Niki Arnogiannaki
Alexandros Tzovaras
Maroulio Talieri
Ioannis Missitzis
Published In
Anticancer Res
In Vivo
Cancers (Basel)
Tumour Biol
Breast Cancer Res Treat
Affiliations
Soon will be listed here.
Recent Articles
1.
A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer
Ardavanis-Loukeris G, Kokkali S, Perdikari K, Karatrasoglou E, Talagani S, Tzovaras A, et al.
Anticancer Res . 2024 Mar; 44(4):1559-1565. PMID: 38537957
Background/aim: Everolimus in combination with exemestane was shown to offer benefit versus exemestane monotherapy in hormone receptor (HR)-positive, HER2-negative advanced breast cancer patients who progressed after aromatase inhibitor (AI) therapy....
2.
Exploring the Use of a Digital Platform for Cancer Patients to Report Their Demographics, Disease and Therapy Characteristics, Age, and Educational Disparities: An Early-Stage Feasibility Study
Galiti D, Linardou H, Agelaki S, Karampeazis A, Tsoukalas N, Psyrri A, et al.
Curr Oncol . 2023 Aug; 30(8):7608-7619. PMID: 37623032
Introduction: The increasing burden of cancer, the development of novel therapies, and the COVID-19 pandemic have made cancer care more complex. Digital innovation was then pushed toward developing platforms to...
3.
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
Mountzios G, Planchard D, Metro G, Tsiouda D, Prelaj A, Lampaki S, et al.
JTO Clin Res Rep . 2023 Feb; 4(1):100433. PMID: 36793384
Introduction: Real-world evidence regarding molecular epidemiology and management patterns of patients with EGFR exon-20 mutated, advanced NSCLC outside the context of clinical trials is lacking. Methods: We created a European...
4.
Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
Kokkali S, Kyriazoglou A, Mangou E, Economopoulou P, Panousieris M, Psyrri A, et al.
J Clin Med . 2023 Feb; 12(3). PMID: 36769769
Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical...
5.
Association between Intratumoral CD8+ T Cells with FoxP3+ and CD163+ Cells: A Potential Immune Intrinsic Negative Feedback Mechanism for Acquired Immune Resistance
Fortis S, Sofopoulos M, Goulielmaki M, Arnogiannaki N, Ardavanis A, Perez S, et al.
Cancers (Basel) . 2022 Dec; 14(24). PMID: 36551693
Acquired immune resistance (AIR) describes a situation in which cancer patients who initially responded clinically to immunotherapies, after a certain period of time, progress with their disease. Considering that AIR...
6.
Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients
Balalis D, Tsakogiannis D, Kalogera E, Kokkali S, Tripodaki E, Ardavanis A, et al.
J Clin Med . 2022 Jul; 11(14). PMID: 35887839
Background: Angiogenesis is a hallmark of breast cancer (BC) and is mediated by the vascular endothelial growth factor (VEGF) signaling axis. It is regulated by different proangiogenic factors, including platelet-derived...
7.
A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients' Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece
Kokkali S, Boukovinas I, Samantas E, Papakotoulas P, Athanasiadis I, Andreadis C, et al.
Cancers (Basel) . 2022 Apr; 14(8). PMID: 35454787
This non-interventional, multicenter, prospective study aimed to evaluate the real-world activity of trabectedin, and its impact on symptom burden and quality of life in patients with advanced soft tissue sarcoma...
8.
The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis
Kokkali S, Kotsantis I, Magou E, Sophia T, Kormas T, Diakoumis G, et al.
Invest New Drugs . 2022 Mar; 40(3):668-675. PMID: 35312944
Background: Current treatment recommendations for high grade non-metastatic osteosarcoma include perioperative chemotherapy and surgery. Despite this intensive protocol, approximately 40% of patients will relapse. The addition of the immunomodulator mifamurtide...
9.
Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence
Christopoulou A, Ardavanis A, Papandreou C, Koumakis G, Papatsimpas G, Papakotoulas P, et al.
Oncol Lett . 2022 Mar; 23(4):115. PMID: 35251346
Thromboprophylaxis, as a preventive measure for cancer-associated thrombosis (CAT), may be beneficial for patients with active cancer and high-risk for thrombosis. The present post hoc analysis include a total of...
10.
Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group
Kokkali S, Saloustros E, Stefanou D, Makrantonakis P, Kentepozidis N, Boukovinas I, et al.
Curr Oncol . 2022 Feb; 29(2):1237-1251. PMID: 35200604
Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were...